Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE American Society of Anesthesiologists
SAN FRANCISCO and PARK RIDGE, Ill., Oct. 14, 2013 /PR Newswire-USNewswire/ -- Menopausal women suffer from half as many hot flashes after receiving a non-hormonal chronic pain treatment, according to a study presented at the ANESTHESIOLOGY™ 2013 annual meeting. The nerve block treatment interrupts the area of the brain that regulates body temperature, reducing moderate-to-severe hot flashes and alleviating depression in menopausal women, breast cancer patients and women in surgical menopause.
"Hot flashes affect more than 80 percent of menopausal women," said David R. Walega, M.D., chief of the Division of Pain Medicine, and program director of the Multidisciplinary Pain Medicine Fellowship, Department of Anesthesiology at Northwestern University Feinberg School of Medicine, Chicago.
"This is the first effective, non-hormonal treatment for hot flashes, which for many women have a serious negative effect on their lives. This treatment will also help breast cancer patients who suffer from hot flashes as a side effect of their treatments or medication. Some breast cancer patients stop taking their medication (tamoxifen) because of hot flashes."
Hot flashes are a sudden feeling of heat or warmth starting in the face and extending to the neck and chest area. Some women also experience profuse sweating and a "reddening" or flush to their skin. Hot flashes can last anywhere from one to 10 minutes and vary in strength and frequency.
This prospective, randomized, controlled study included 40 patients between 30 and 65 years old who experienced at least 25 hot flashes per week. Half of the participants received a stellate ganglion blockade (SGB) injection with a local anesthetic. A SGB blockade was injected in the neck about two inches to the right of the voice box. The other 20 patients received an injection of sterile saline. The patients recorded the daily number of hot flashes in a journal and were followed for six months. The study participants were also objectively assessed by a Core Temperature Monitor, which measures changes in a person's skin conductants.
Moderate to severe hot flashes decreased 50 percent for women who received the SGB injection. Dr. Walega also observed a 30 percent decrease in depression and a 10 percent improvement in verbal learning. These findings were important as loss of memory and cognition are another frequent concern of women in menopause who have hot flashes.
"This is a fast, relatively painless, long-lasting and cost-effective treatment for hot flashes," continued Dr. Walega. "It has tremendous potential to help not only menopausal women, but also breast cancer patients and women in surgical menopause (whose ovaries have been removed), who have had to put up with ineffective treatments or simply 'grin and bear it.'"
The American Society of Anesthesiologists
Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 50,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.
For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount. Join the ANESTHESIOLOGY™ 2013 social conversation today. Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES2013.
This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.
©2012 PR Newswire. All Rights Reserved.